Parathyroid hormone analogue
Teriparatide
An established bone-anabolic peptide medicine with fracture-prevention evidence that should not be generalized to every healing claim.
Also known as Forteo · PTH 1-34 · recombinant human parathyroid hormone 1-34
01 · Evidence profile
One molecule, four evidence questions
Randomized evidence supports vertebral and nonvertebral fracture-risk reduction in defined osteoporosis populations.
Bone-turnover, exposure, and product-specific pharmacology are well characterized.
Labels describe hypercalcemia, orthostatic hypotension, osteosarcoma risk factors, and other precautions.
High for authentic approved products used within the label.
02 · Identity
What it is
Teriparatide is the biologically active 1-34 fragment of human parathyroid hormone and is used as an anabolic osteoporosis medicine.
03 · Product identity
The molecule is not the finished product.
Teriparatide evidence concerns approved drug products and labeled osteoporosis populations, not every product called PTH 1-34 or every type of fracture.
Forteo
2024 label- Formulation
- Prefilled delivery device
- Route
- Subcutaneous
- Indication scope
- Osteoporosis uses in the high-fracture-risk populations defined in the product label.
- Forteo
- approved teriparatide products
- Osteoporosis treatment in labeled high-fracture-risk populations
04 · Evidence snapshot
What the evidence can and cannot say
Controlled trials and approved labeling support reduction of vertebral and nonvertebral fracture risk in defined high-risk osteoporosis populations.
That evidence does not prove faster healing for every acute fracture, universal benefit in athletes, or safety outside monitored prescription use.
05 · Claim check
Three claims under the lens
“Teriparatide reduces fracture risk in defined osteoporosis populations.”
The pivotal evidence and label support vertebral and nonvertebral fracture-risk reduction in studied high-risk populations.
- Evidence basis
- Randomized human outcomes
- Scope
- Labeled osteoporosis populations at high fracture risk.
“Teriparatide is proven to heal every fracture faster.”
Fracture prevention and acute fracture healing are different endpoints, and trial results vary by fracture setting.
- Evidence basis
- Randomized human outcomes
- Scope
- Acute fracture-healing outcomes across all fracture types.
“Because teriparatide is a peptide, it has no serious risks.”
The current label includes clinically important warnings, precautions, and population restrictions.
- Evidence basis
- Regulatory or product record
- Scope
- Approved teriparatide product use.
06 · Safety boundary
Before this becomes personal
The label contains important duration, risk-factor, calcium, and monitoring considerations. No dose, injection, or off-label fracture-healing instructions are provided.
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
Reviewed 2026-07-23. This status is not personal clearance to compete.07 · Sources
Check the primary record
08 · Provenance
Review history
Initial brief based on the current Forteo label and fracture-prevention trial record.
Responsible editor: Anthony Treviso. Editorial source review completed. This page has not been independently medically reviewed by a physician or pharmacist.